ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / SNGX
LEXX (34) MTVA (31) TCRT (36) KPRX (30) ⌘ Pro Terminal →

Soligenix Inc. (SNGX) — RQD Stock Rating Cockpit

$0.36 -3.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.36

Soligenix Inc. (SNGX) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • SELL / AVOID Cap $8.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SNGX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SNGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Soligenix Inc. (NASDAQ: SNGX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.36 (-3.63% 1D, market cap $8.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SNGX ranks #488 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SNGX compare to LEXX and MTVA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SNGX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LEXX (Lexaria Bioscience Corp.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $7.9M) and MTVA (MetaVia Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M). Among the 5-stock peer group, SNGX leads on earnings multiple (N/A) while SNGX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SNGX?
▼

Per SNGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000812796), Soligenix Inc. generated $0 in revenue (-100.0% YoY), -$11.1M in net income, and -$10.3M in free cash flow against $9.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.36 (-0.84%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510042
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (7)Whales (11)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-8.3% Base Target
$2 Bull$0 Base$0 Bear
📬 FREE SNGX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SNGX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY SNGX SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
34
Grade E$0.35-2.9% Next Q
Q2 (-2Q)
37
Grade E$0.34+2.9% Next Q
Q3 (-1Q)
39
Grade E$0.35+2.9% Next Q
Current
42
Grade D-$0.36-7% Hist 90D α
Trajectory: E (34) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SNGX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SNGX currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.37) and Max Pain ($0.38) forces dealer call-delta covering toward $1.78.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SNGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SNGX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 42%NO 58%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
53.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE6% OF RANGE
L: $0$0.36H: $2
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on SNGX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (42)

16/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like SNGX
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNGX)

  • ✓Walkthrough of SNGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SNGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.86%⚡ TESTING RESISTANCE
2026-11-02O $0.38H $0.38L $0.36C $0.36VOL 36.8K
RES: $0.38SUP: $0.30SMA50: $0.37SMA200: $0.68
$1.72$1.33$0.94$0.55$0.16RES $0.38SUP $0.30$0.362026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SNGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SNGX Butterfly Map → + Track SNGX →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SNGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SNGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SNGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNGX)

Health Care Rank #488 of 1016 ⚔️ LEXX vs SNGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SNGX vs. LEXX, MTVA, TCRT, KPRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Soligenix Inc. (SNGX) ranks #488 by composite RQD confidence (42/100, grade D-) and #910 by equity capitalization ($8.0M). Within this direct 5-issuer industry benchmark cohort, SNGX leads on earnings valuation at N/A trailing P/E, while SNGX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SNGX currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SNGX ACTIVE
Soligenix Inc.
D- 42/100 — — -35.0% -3.63% $8.0M Benchmark Subject
LEXX
Lexaria Bioscience Corp.
E 34/100 — 96.0% -35.0% -7.43% $7.9M /lexx-vs-sngx →
MTVA
MetaVia Inc.
E 31/100 — — -35.0% -5.88% $7.8M /mtva-vs-sngx →
TCRT
Alaunos Therapeutics Inc.
D- 36/100 — — -35.0% +3.18% $7.8M /tcrt-vs-sngx →
KPRX
Kiora Pharmaceuticals Inc.
E 30/100 — — -35.0% -11.36% $7.8M /kprx-vs-sngx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000812796

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Soligenix Inc. (SNGX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $119.4K , and -100.0% cumulative change since FY2023) , GAAP net income of -$11.1M, operating cash flow of -$10.3M, and free cash flow of -$10.3M (-22.2% YoY). On the balance sheet, SNGX closed FY2025 with $9.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$11.1M -$10.3M -$10.3M $9.2M —
FY2024 (FY) 2024-12-31 $119.4K -$8.3M -$8.4M -$8.4M $9.0M —
FY2023 (FY) 2023-12-31 $839.4K -$6.1M -$8.6M -$8.6M — —

3. SNGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SNGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Soligenix Inc. (NASDAQ: SNGX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.36 (-3.63% 1D, market cap $8.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SNGX ranks #488 in composite RQD confidence.

How does SNGX compare to LEXX and MTVA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SNGX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LEXX (Lexaria Bioscience Corp.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $7.9M) and MTVA (MetaVia Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M). Among the 5-stock peer group, SNGX leads on earnings multiple (N/A) while SNGX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SNGX?

Per SNGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000812796), Soligenix Inc. generated $0 in revenue (-100.0% YoY), -$11.1M in net income, and -$10.3M in free cash flow against $9.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SNGX trading relative to its 50-day, 200-day, and 52-week technical levels?

SNGX last traded at $0.36 (-3.63% on volume of 69,705 shares), positioning the stock -2.70% below its 50-day simple moving average ($0.37) and -47.06% below its 200-day simple moving average ($0.68). Across its 52-week range of $0.28 to $1.70, SNGX sits at the 5.6% percentile with a 14-day RSI of 53.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.40).

SNGX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell SNGX stock right now?

Soligenix Inc. (SNGX) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is SNGX's 12-month price target and RQD AI Jury consensus?

SNGX's 12-month base price target is $0.33 (range $0.26 to $1.78), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: SNGX RQD Cockpit SNGX 12M Forecast SNGX Earnings & Move SNGX Dividends & DRIP SNGX Insiders & 13F SNGX Whale Options SNGX Profit Sankey SNGX News & Why
ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SNGX — Soligenix Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:52:20Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 42 / D- (Roarable Sell — Vulnerable Balance Sheet & Flow), per the Roarable RQD rating. The five pillars are:

  • Fundamental Cash Engine: 7 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and FCF yield of 0%. For an investor, this indicates the business is not currently generating returns on invested capital or free cash flow available to shareholders.
  • Whale / 13F Flow: 11 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The source data does not provide the underlying 13F holdings, so the component cannot be traced further.
  • Insider Conviction: 5 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the lowest-scoring pillar in relative terms and signals limited insider-driven confidence in the rating's view.
  • Macro Regime Fit: 9 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. A beta of 1.0 means the stock is expected to move in line with the broader market per the market data.
  • Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These mixed readings point to a balance sheet that is not clearly distressed but carries weak quality signals.

Taken together, the rating points to limited cash generation, weak forensic quality, and modest institutional and insider support. Upside drivers in this framework would have to come from improved cash generation or a change in flow signals; the source data does not identify specific catalysts that would produce that change. Valuation tradeoffs cannot be assessed quantitatively because P/E, EV/EBITDA, and EPS are not available in source data.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-11.8M$-11.1MN/A$-10.3MN/AN/A
FY 2024$0.1M$-9.4M$-8.3MN/A$-8.4MN/AN/A
FY 2023$0.8M$-7.7M$-6.1MN/A$-8.6MN/AN/A

Per the SEC financials, the company reported operating losses in each period, with operating income of $-11.8M in FY 2025. Gross, operating, and net margins are each recorded at 0% in the market data, and ROIC is -35%. Per the Roarable RQD rating, Altman Z-Score is 2.5, Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Cash and debt balances by period are N/A in the SEC financials.

Recent Catalysts & News Wire Analysis

The news feed contains six items, all tagged to SNGX and all carrying a YELLOW light and MARKET WIRE impact label. Items include a StockInvest.us forecast article, a Yahoo Finance UK seasonal returns chart, a TradingView estimates page, two Form 4 filing notices for director Robert J. Rubin (one dated 12 October and one dated 17 September), and a TradingView Q3'26 earnings item listing a revenue estimate of 0 USD. The feed describes these as general market coverage; it does not identify specific product or regulatory catalysts. Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links or proprietary signals.

SNGX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Soligenix Inc. (SNGX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SNGX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SNGX Bull vs. Bear Conversation Board — What's Your Call at $0.36?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SNGX 🐻 67% BEARISH CONVICTION
1. Pick Your Side on SNGX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.33 (-10.8%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SNGX (D- • RQD 42/100) a Buy at $0.37?

Welcome to the SNGX (Soligenix Inc.) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.29 (-21.6%)
Spot @ $0.37

Pump the brakes on SNGX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SNGX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Soligenix Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.42 (+13.5%)
Spot @ $0.37

SNGX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SNGX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.37 (52-wk range $0.28 - $1.70), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%